JP2017214418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017214418A5 JP2017214418A5 JP2017157337A JP2017157337A JP2017214418A5 JP 2017214418 A5 JP2017214418 A5 JP 2017214418A5 JP 2017157337 A JP2017157337 A JP 2017157337A JP 2017157337 A JP2017157337 A JP 2017157337A JP 2017214418 A5 JP2017214418 A5 JP 2017214418A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- aryl
- divalent
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361773778P | 2013-03-06 | 2013-03-06 | |
| US61/773,778 | 2013-03-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561540A Division JP6196328B2 (ja) | 2013-03-06 | 2014-03-04 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019043933A Division JP6672499B2 (ja) | 2013-03-06 | 2019-03-11 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017214418A JP2017214418A (ja) | 2017-12-07 |
| JP2017214418A5 true JP2017214418A5 (cg-RX-API-DMAC7.html) | 2019-01-31 |
| JP6496788B2 JP6496788B2 (ja) | 2019-04-03 |
Family
ID=50389505
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561540A Expired - Fee Related JP6196328B2 (ja) | 2013-03-06 | 2014-03-04 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2017157337A Expired - Fee Related JP6496788B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2017157336A Expired - Fee Related JP6496787B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2019043933A Expired - Fee Related JP6672499B2 (ja) | 2013-03-06 | 2019-03-11 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561540A Expired - Fee Related JP6196328B2 (ja) | 2013-03-06 | 2014-03-04 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157336A Expired - Fee Related JP6496787B2 (ja) | 2013-03-06 | 2017-08-17 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP2019043933A Expired - Fee Related JP6672499B2 (ja) | 2013-03-06 | 2019-03-11 | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20140256685A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2964214A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6196328B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20210024691A (cg-RX-API-DMAC7.html) |
| CN (2) | CN105007908B (cg-RX-API-DMAC7.html) |
| AR (1) | AR095035A1 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014226001B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112015021392B1 (cg-RX-API-DMAC7.html) |
| CA (3) | CA3114477A1 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1219661A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2696487C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201446241A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014138046A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX376348B (es) | 2011-10-26 | 2025-03-07 | Allergan Inc | Derivados de amida de aminoacidos sustituidos con n-urea como moduladores de receptor de tipo peptido receptor de formilo-1 (fprl-1). |
| AU2013249474A1 (en) * | 2012-04-16 | 2014-11-06 | Allergan, Inc. | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| EP2850058B1 (en) | 2012-05-16 | 2016-07-13 | Actelion Pharmaceuticals Ltd. | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| KR20210024691A (ko) * | 2013-03-06 | 2021-03-05 | 알러간, 인코포레이티드 | 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도 |
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| EP3022174B1 (en) * | 2013-07-16 | 2018-09-05 | Allergan, Inc. | Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators |
| BR112016001106A8 (pt) | 2013-07-18 | 2017-12-26 | Actelion Pharmaceuticals Ltd | Derivados de espiro [2,4] heptano interligados piperazina substituídos como agonistas do receptor de alx |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| WO2015116566A1 (en) * | 2014-01-29 | 2015-08-06 | Allergan, Inc. | 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| EP3145916B1 (en) | 2014-05-21 | 2020-02-12 | Allergan, Inc. | Imidazole derivatives as formyl peptide receptor modulators |
| BR112018011046A2 (pt) * | 2015-12-10 | 2018-11-21 | Bristol-Myers Squibb Company | agonistas receptores de piperidinona formil peptí-deo 2 e de formil peptídeo 1 |
| CA3017967A1 (en) | 2016-03-28 | 2017-10-05 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
| JP2019515901A (ja) * | 2016-04-12 | 2019-06-13 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｎ−ホルミルペプチド受容体モジュレータとしてのフェニル尿素誘導体 |
| MX2019003867A (es) | 2016-10-06 | 2019-08-05 | Daiichi Sankyo Co Ltd | Derivado de urea. |
| GB2561540A (en) * | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| ES2799098B2 (es) * | 2019-06-10 | 2021-12-10 | Univ Madrid Carlos Iii | Aptameros agonistas del receptor fpr2 y usos de los mismos |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| JPS63232846A (ja) | 1987-03-20 | 1988-09-28 | Haruo Ogura | 新規な固定相担体 |
| AU6909300A (en) * | 1999-08-20 | 2001-03-19 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
| DE10005275A1 (de) * | 2000-02-07 | 2001-08-09 | Bayer Ag | Neuartige Glycokonjugate |
| EP1162194A1 (en) | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| CN100497302C (zh) * | 2002-09-05 | 2009-06-10 | 神经研究公司 | 二芳基脲衍生物和它们作为氯通道阻滞剂的用途 |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| JP4769082B2 (ja) | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | ウレア誘導体、その製造法及び用途 |
| WO2006065755A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
| WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| KR20090121832A (ko) * | 2008-05-23 | 2009-11-26 | 인제대학교 산학협력단 | 2-(2-히드록시벤조일)히드라진카르복시아미드 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를유효 성분으로 함유하는 선택적 면역 억제용 약학적 조성물 |
| EP2362866B1 (en) * | 2008-11-11 | 2015-07-08 | Signum Biosciences, Inc. | Isoprenyl compounds and methods thereof |
| KR20100101054A (ko) * | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| WO2011073918A2 (en) * | 2009-12-16 | 2011-06-23 | Actelion Pharmaceuticals Ltd | Peptides as modulators of fprl1 and/or fprl2 |
| AU2011270872A1 (en) * | 2010-06-24 | 2013-01-31 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity |
| CA2819457A1 (en) * | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| US8580817B2 (en) | 2011-02-11 | 2013-11-12 | Allergan, Inc. | 1-(1-OXO-1,2,3,4-tetrahydroisoquinolin-7-YL)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8653299B2 (en) | 2011-03-17 | 2014-02-18 | Allergan, Inc. | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US20120329873A1 (en) | 2011-06-17 | 2012-12-27 | Li yong-xin | D-serine for the treatment of visual system disorders |
| EP2731931A1 (en) * | 2011-07-11 | 2014-05-21 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| MX376348B (es) * | 2011-10-26 | 2025-03-07 | Allergan Inc | Derivados de amida de aminoacidos sustituidos con n-urea como moduladores de receptor de tipo peptido receptor de formilo-1 (fprl-1). |
| US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| EP2814815A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators |
| AU2013249474A1 (en) * | 2012-04-16 | 2014-11-06 | Allergan, Inc. | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| KR20210024691A (ko) * | 2013-03-06 | 2021-03-05 | 알러간, 인코포레이티드 | 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도 |
| US9850264B2 (en) * | 2013-03-06 | 2017-12-26 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| EP3022174B1 (en) * | 2013-07-16 | 2018-09-05 | Allergan, Inc. | Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators |
| WO2015042071A1 (en) | 2013-09-19 | 2015-03-26 | Allergan, Inc. | Diphenyl urea derivatives as formyl peptide receptor modulators |
| RU2703725C1 (ru) | 2013-11-21 | 2019-10-22 | Аллерган, Инк. | Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора |
| EP3145916B1 (en) * | 2014-05-21 | 2020-02-12 | Allergan, Inc. | Imidazole derivatives as formyl peptide receptor modulators |
-
2014
- 2014-03-04 KR KR1020217005968A patent/KR20210024691A/ko not_active Ceased
- 2014-03-04 WO PCT/US2014/020273 patent/WO2014138046A1/en not_active Ceased
- 2014-03-04 CA CA3114477A patent/CA3114477A1/en not_active Abandoned
- 2014-03-04 CA CA3114347A patent/CA3114347A1/en not_active Abandoned
- 2014-03-04 JP JP2015561540A patent/JP6196328B2/ja not_active Expired - Fee Related
- 2014-03-04 US US14/196,155 patent/US20140256685A1/en not_active Abandoned
- 2014-03-04 KR KR1020157024039A patent/KR102223384B1/ko not_active Expired - Fee Related
- 2014-03-04 AU AU2014226001A patent/AU2014226001B2/en not_active Ceased
- 2014-03-04 CA CA2899804A patent/CA2899804A1/en not_active Abandoned
- 2014-03-04 HK HK16107753.4A patent/HK1219661A1/zh unknown
- 2014-03-04 CN CN201480011861.8A patent/CN105007908B/zh not_active Expired - Fee Related
- 2014-03-04 CN CN201711029910.2A patent/CN107714683A/zh active Pending
- 2014-03-04 RU RU2015134778A patent/RU2696487C2/ru active
- 2014-03-04 BR BR112015021392-8A patent/BR112015021392B1/pt not_active IP Right Cessation
- 2014-03-04 BR BR122017004256A patent/BR122017004256A2/pt not_active Application Discontinuation
- 2014-03-04 EP EP14713302.9A patent/EP2964214A1/en not_active Withdrawn
- 2014-03-06 TW TW103107759A patent/TW201446241A/zh unknown
- 2014-03-06 AR ARP140100733A patent/AR095035A1/es unknown
-
2017
- 2017-04-18 US US15/490,127 patent/US10434112B2/en not_active Expired - Fee Related
- 2017-08-17 JP JP2017157337A patent/JP6496788B2/ja not_active Expired - Fee Related
- 2017-08-17 JP JP2017157336A patent/JP6496787B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-22 HK HK18110777.8A patent/HK1251185A1/zh unknown
-
2019
- 2019-03-06 AU AU2019201538A patent/AU2019201538B2/en not_active Ceased
- 2019-03-11 JP JP2019043933A patent/JP6672499B2/ja not_active Expired - Fee Related
- 2019-09-10 US US16/566,682 patent/US10799518B2/en not_active Expired - Fee Related
-
2020
- 2020-09-22 US US17/028,440 patent/US20210008085A1/en not_active Abandoned
- 2020-09-22 US US17/028,416 patent/US20210000846A1/en not_active Abandoned
-
2021
- 2021-05-18 AU AU2021203183A patent/AU2021203183A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017214418A5 (cg-RX-API-DMAC7.html) | ||
| JP2017214417A5 (cg-RX-API-DMAC7.html) | ||
| JP2017066164A5 (cg-RX-API-DMAC7.html) | ||
| JP2017214416A5 (cg-RX-API-DMAC7.html) | ||
| JP2018009012A5 (cg-RX-API-DMAC7.html) | ||
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| BR112015005331B8 (pt) | Eletrólito de polímero em gel e dispositivo eletroquímico incluindo o mesmo | |
| MX385158B (es) | Derivados indol para uso en medicina. | |
| NZ734896A (en) | Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | |
| TW200800945A (en) | Macrocylic inhibitors of hepatitis c virus | |
| DOP2010000219A (es) | Derivados de ftalazinona | |
| CY1120477T1 (el) | Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων | |
| CO6180506A2 (es) | Inhibidores de la proteasa ns3 del hcv | |
| ES2570177T3 (es) | Compuesto heterocíclico | |
| AR091858A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| RU2011135977A (ru) | Производное n-ацилантраниловой кислоты или его соль | |
| BR112012033690A2 (pt) | sais de cálcio de compostos como agentes anti-inflamatórios, imunomodulares e antitroliferativos | |
| EA201170522A1 (ru) | Новые гетероциклические азотсодержащие соединения, их получение и их применение в качестве антибактериальных лекарственных средств | |
| AR091857A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| WO2008126804A1 (ja) | レジスト下層膜形成組成物 | |
| EA201270359A1 (ru) | Терапевтическое средство от расстройств настроения | |
| JP2016529235A5 (cg-RX-API-DMAC7.html) | ||
| BR112018076686A2 (pt) | composição para a remoção de composto que contém enxofre | |
| JP2019500319A5 (cg-RX-API-DMAC7.html) | ||
| RU2015148268A (ru) | Способ получения 1,2-бензизотиазолин-3-онов |